RSV is a common respiratory virus, usually with mild symptoms, but it can have serious consequences for vulnerable people, especially the elderly.
Today, the Commission approved the mRNA vaccine ‘mResvia’ for the immunization of adults over 60 years of age against lower respiratory tract disease caused by respiratory syncytial virus (RSV) infection.
RSV is a common respiratory virus, usually with mild symptoms, but it can have serious consequences for vulnerable people, especially the elderly.
The Commissioner for Health and Food Safety, Ms. Stella Kyriakidou, said: “Vaccination saves lives. In a strong European Health Union, we are determined to ensure that all citizens have access to the protection they need against serious illness. The approval of the first mRNA vaccine against RSV clearly shows how important innovation is to protect the health of our citizens.”
The mResvia vaccine was approved before the autumn/winter season, when respiratory infections such as RSV usually peak in the EU. It was preceded by a positive scientific evaluation by the European Medicines Agency (EMA) in June 2024. It is now up to the national authorities of each member state to decide whether and how to use the vaccine, according to their national vaccination plans.
The mResvia vaccine, developed by Moderna, is the first mRNA vaccine approved in the EU for a disease other than COVID-19. In 2023 the Commission approved other RSV vaccines to protect vulnerable groups, including infants.
George Fellidis
Source :Skai
With a wealth of experience honed over 4+ years in journalism, I bring a seasoned voice to the world of news. Currently, I work as a freelance writer and editor, always seeking new opportunities to tell compelling stories in the field of world news.
